title: BZLF1 controlled by family repeat domain induces lytic cytotoxicity in Epstein-Barr virus-positive tumor cells.
abstract: BACKGROUND
  BZLF1, an EBV (Epstein-Barr virus) immediate early gene, is required for EBV lytic replication that causes the death of host cells. EBNA1, the product of EBV latent gene, binds to the family repeats (FR) of the origin of replication (Orip) regulating EBV replication.
  
  
  METHODS
  A vector pFR-Z (BZLF1 controlled by FR domain of EBV) was constructed and transfected into EBV-positive 5-8F and-negative HNE3 nasopharyngeal carcinoma cells and BZLF1-induced cytotoxicity was tested.
  
  
  RESULTS
  EBNA1 expression was detected in 5-8F but not HNE3 cells and, in agreement, pFR controlled luciferase expression was activated in 5-8F cells but inhibited in HNE3 cells. Gardella gel assay demonstrated that pFR-Z effectively induced EBV lytic replication in 5-8F but not HNE3 cells. The lytic cytotoxicity was confirmed by a diminished cell survival and the induction of lytic proteins EA-D and gp125. The cytotoxicity was also strikingly enhanced by addition of GCV (gancyclovir) that kill cells with lytic form EBV.
  
  
  CONCLUSIONS
  pFR-Z is a specific gene therapy vehicle for EBV-positive carcinomas.
authors.affiliation: Cancer Research Institute, Xiangya School of Medicine, Central South University, Changsha, Hunan 410078, China.
authors.forename: Hai
authors.initials: H
authors.lastname: Wang
authors.forename: Yan
authors.initials: Y
authors.lastname: Zhao
authors.forename: Liang
authors.initials: L
authors.lastname: Zeng
authors.forename: Min
authors.initials: M
authors.lastname: Tang
authors.forename: Amany
authors.initials: A
authors.lastname: El-Deeb
authors.forename: Jian Jian
authors.initials: JJ
authors.lastname: Li
authors.forename: Ya
authors.initials: Y
authors.lastname: Cao
mesh_terms: D045744:Cell Line, Tumor; D004279:DNA, Viral / Q000235:genetics; D004268:DNA-Binding Proteins / Q000096:biosynthesis / Q000235:genetics*; D004742:Enhancer Elements, Genetic; D020031:Epstein-Barr Virus Infections / Q000378:metabolism / Q000821:virology; D019309:Epstein-Barr Virus Nuclear Antigens / Q000096:biosynthesis / Q000235:genetics; D015774:Ganciclovir / Q000494:pharmacology; D015316:Genetic Therapy / Q000379:methods; D005822:Genetic Vectors / Q000235:genetics; D004854:Herpesvirus 4, Human / Q000235:genetics / Q000378:metabolism / Q000502:physiology*; D006801:Humans; D009303:Nasopharyngeal Neoplasms / Q000235:genetics / Q000378:metabolism / Q000628:therapy / Q000821:virology*; D010957:Plasmids / Q000235:genetics; D016133:Polymerase Chain Reaction; D012091:Repetitive Sequences, Nucleic Acid; D018741:Replication Origin / Q000235:genetics; D015534:Trans-Activators / Q000096:biosynthesis / Q000235:genetics*; D014162:Transfection; D014412:Tumor Virus Infections / Q000378:metabolism / Q000821:virology; D014764:Viral Proteins / Q000096:biosynthesis / Q000235:genetics*; D014779:Virus Replication / Q000235:genetics
chemical_list: C063676:BZLF1 protein, Herpesvirus 4, Human; D004279:DNA, Viral; D004268:DNA-Binding Proteins; D019309:Epstein-Barr Virus Nuclear Antigens; D015534:Trans-Activators; D014764:Viral Proteins; C417029:EBV-encoded nuclear antigen 1; D015774:Ganciclovir